New York State Common Retirement Fund Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New York State Common Retirement Fund lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,934 shares of the company's stock after selling 10,295 shares during the period. New York State Common Retirement Fund owned approximately 0.10% of IDEXX Laboratories worth $40,889,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. International Assets Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of IDEXX Laboratories by 696.0% in the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock valued at $171,891,000 after purchasing an additional 308,493 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock valued at $111,229,000 after purchasing an additional 213,731 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of IDEXX Laboratories by 46.0% in the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after purchasing an additional 177,226 shares in the last quarter. Finally, 1832 Asset Management L.P. grew its holdings in shares of IDEXX Laboratories by 4,193.1% in the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock valued at $62,601,000 after purchasing an additional 125,498 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $10.36 during mid-day trading on Friday, reaching $417.28. 994,156 shares of the company's stock were exchanged, compared to its average volume of 675,492. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 52-week low of $395.37 and a 52-week high of $583.39. The company has a market cap of $34.35 billion, a price-to-earnings ratio of 40.24, a PEG ratio of 3.55 and a beta of 1.36. The company has a 50-day simple moving average of $478.76 and a two-hundred day simple moving average of $487.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. The company's quarterly revenue was up 6.6% compared to the same quarter last year. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a "neutral" rating for the company in a report on Wednesday, August 14th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. BTIG Research started coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a "buy" rating and a $580.00 price target for the company. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $574.13.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.